SuzyKnew! hates to be the bearer of bad news – especially when it comes to a lady’s sexual health. But, by all accounts, Addyi – the so-called female Viagra – is a flop! And, SuzyKnew! had such high hopes.
Late last month researchers reported that the average benefit women receive from taking the daily pill is an additional one half of one satisfying sexual encounter a month. Don’t ask what “one half” of a satisfying sexual encounter is. The study was published in JAMA Internal Medicine showing results were weaker than those submitted to the FDA during the drug approval process.
In December of last year, Cindy Whitehead, the CEO of Sprout, the pharma company that introduced Addyi, stepped down. And,Valeant, the company that acquired Addyi for $1 billion in August 2015, has been under the spotlight for questionable accounting practices for nearly two years. Today, the drug maker’s stock plunged 51% reporting its worst day ever.
Sales of Addyi have been very weak and disappointing, especially given the high price Valeant paid to acquire the drug. Instead of generating the expected $100 – $150 million in sales for the year, Addyi is only pulling in around the equivalent of $11 million. Click here for a news video
Hopefully, this isn’t the end of trying to find solutions – both natural and pharmaceutical – for low libido in women. Let a sista’ know!
